Health plans have long struggled with a fundamental question: when is a drug claim tied to 340B pricing, and what does that mean financially?
In 2026, the HHS Office of Inspector General (OIG) requested Medicare Advantage plans to begin reporting and strengthening visibility into 340B indicators on claims. This signals a clear shift. Regulators are no longer treating 340B as a siloed Covered Entity issue.
At the same time, the financial exposure for plans continues to grow.
Why This Matters Now
The 340B program has scaled significantly, with covered entity purchases exceeding $80 billion and contract pharmacy networks expanding across retail chains, PBMs, and specialty pharmacies.
But visibility, oversight, and transparency have not kept pace.
Health plans may be paying full reimbursement even when 340B acquisition economics exist elsewhere in the transaction. At the same time, expected manufacturer rebates may be reduced, denied, or retrospectively removed, while stakeholders lack a clear view into the underlying economics. The result is that plans can overpay, under-collect rebates, and misstate net drug cost all at once.
Expectations are also increasing. Plans are now under pressure to capture 340B indicators at the claim level, reconcile claims against rebate eligibility and exclusions, and demonstrate how 340B status impacts payment, rebate outcomes, and member cost sharing. Without this level of visibility, plans risk losing margin while simultaneously underreporting the true drivers of trend
Forward-looking plans are treating 340B as a data and governance priority, not a niche pharmacy issue. Key actions include:
- Integrating medical and pharmacy drug data at the claim level
- Capturing all available 340B indicators, even if incomplete
- Mapping claims to covered entities and contract pharmacies
- Reconciling paid claims to rebate invoicing and payment outcomes
- Building employer-facing reporting on 340B-related impact
The policy debate around 340B will continue. But for health plans, the more immediate issue is operational. Do you know which claims are affected, how they are priced, and whether rebates and member costs reflect that reality, or are you absorbing hidden cost and missed value?
